Proposed Diagnostic and Interventional Radiology MVPs
ACR provided comments on the proposed diagnostic and interventional radiology MVPs under consideration for 2026 rulemaking.
Read moreMain Content
ACR Provides Insights on AI Oversight, Use and Innovation in Response to Congressional Request For Information
May 9, 2024
The American College of Radiology® (ACR®) responded to a targeted request for information from U.S. Rep. Ami Bera, MD, (CA-6), a member of the bipartisan House Task Force on Artificial Intelligence (AI), regarding the state of health care artificial intelligence (AI). Rep. Bera’s RFI included an extensive list of questions focused on various aspects of healthcare AI oversight, implementation, use and innovation.
ACR highlighted examples of real-world applications of healthcare AI and recommended ways to enhance product transparency and oversight mechanisms moving forward, including leveraging public-private partnerships. The College provided concepts that would be important in any future value-based payment approach looking at ensuring quality implementation, governance and use of high-value AI tools. ACR noted that not all currently reimbursed uses of AI are adding value to patients or the health system.
ACR also highlighted novel oversight questions posed by foundation models/generative AI used to enable higher risk functions such as diagnosis or treatment. The College noted the U.S. Food and Drug Administration may benefit from expanded authorities to meet future regulatory challenges and opportunities.
For more information about ACR’s AI-related programs and initiatives, visit the ACR Data Science Institute website. For questions about the ACR comment submission or AI oversight policy, contact Michael Peters, ACR Senior Government Affairs Director.
ACR highlighted examples of real-world applications of healthcare AI and recommended ways to enhance product transparency and oversight mechanisms moving forward, including leveraging public-private partnerships. The College provided concepts that would be important in any future value-based payment approach looking at ensuring quality implementation, governance and use of high-value AI tools. ACR noted that not all currently reimbursed uses of AI are adding value to patients or the health system.
ACR also highlighted novel oversight questions posed by foundation models/generative AI used to enable higher risk functions such as diagnosis or treatment. The College noted the U.S. Food and Drug Administration may benefit from expanded authorities to meet future regulatory challenges and opportunities.
For more information about ACR’s AI-related programs and initiatives, visit the ACR Data Science Institute website. For questions about the ACR comment submission or AI oversight policy, contact Michael Peters, ACR Senior Government Affairs Director.
Related ACR News
Join Us at the 2025 QSI Conference
This dedicated gathering, Sept. 9–11 in San Diego, is for those who are passionate about quality improvement, informatics and clinical operations.
Read moreACR Advocates Medicare Pay Fix
The American College of Radiology® (ACR®) has signed on to a multi-specialty statement sent to all representatives expressing disappointment with Congress’ decision not to include an increase to the Medicare Physician Fee Schedule (MPFS) conversion factor (CF).
Read more